drugset / Trial / NCT03209869
Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2
Phase 1
Withdrawn
University of Wisconsin, Madison
Midwest Athletes Against Childhood Cancer, Inc. (MACC Fund) · collabNational Cancer Institute (NCI) · collabSolving Kids' Cancer · collabThe Catherine Elizabeth Blair Memorial Foundation / GWCF · collabWade's Army · collab
NaSingle-groupOpen-labelTreatment
Summary
Subjects with relapsed or refractory neuroblastoma and osteosarcoma will receive ex-vivo expanded and activated natural killer (NK) cells from a haploidentical donor in conjunction with the immunocytokine, hu14.18-IL2.
Timeline
- Start
- 2018-03-12
- Primary completion
- 2022-09-07
- Completion
- 2022-09-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hu14.18-IL2 | Monoclonal antibody | — | Other |
| Subject | omidubicel | Cell therapy | — | Other |